Aminothienopyridazines as imaging probes of tau pathology: A patent evaluation of WO2013090497

Expert Opinion on Therapeutic Patents

Volumn 24, Issue 3, 2014, Pages 355-360

  Ballatore, Carlo ^a,b   Smith III, Amos B ^b   Lee, Virginia M Y ^a   Trojanowski, John Q ^a   Brunden, Kurt R ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Alzheimer's disease; Aminothienopyridazine; Positron emission tomography; Tau

Indexed keywords

AMINOTHIENOPYRIDAZINE; FLUORINE 18; HETEROCYCLIC COMPOUND; PYRIDAZINE DERIVATIVE; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; WO 2013090497;

ALZHEIMER DISEASE; ARTICLE; BINDING AFFINITY; BINDING SITE; BRAIN TISSUE; CLINICAL EFFECTIVENESS; DISEASE COURSE; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG METABOLISM; FLUORINATION; HUMAN; IN VITRO STUDY; NONHUMAN; PATENT; POSITRON EMISSION TOMOGRAPHY; PROTEIN BINDING; TAUOPATHY;

ALZHEIMER DISEASE; ANIMALS; BIOLOGICAL MARKERS; BRAIN; HUMANS; MOLECULAR IMAGING; PATENTS AS TOPIC; POSITRON-EMISSION TOMOGRAPHY; PREDICTIVE VALUE OF TESTS; PYRIDAZINES; RADIOPHARMACEUTICALS; TAU PROTEINS;

EID: 84896734490     PISSN: 13543776     EISSN: 17447674     Source Type: Journal    
DOI: 10.1517/13543776.2014.871526     Document Type: Article

References (22)

1. Lee VMY, Goedert M, Trojanowski JQ. Neurodegenerative tauopathies. Annu Rev Neurosci 2001;24:1121-59
2. Arriagada PV, Growdon JH, Hedley-Whyte ET, et al. Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimers disease. Neurology 1992;42:631-9
3. Braak H, Braak E. Neuropathological staging of Alzheimer-related changes. Acta Neuropathol (Berl) 1991;82:239-59
4. Wilcock GK, Esiri MM. Plaques, tangles and dementia. A quantitative study. J Neurol Sci 1982;56:343-56
5. Furumoto S, Okamura N, Iwata R, et al. Recent advances in the development of amyloid imaging agents. Curr Top Med Chem 2007;7(18):1773-89. Review article on amyloid imaging agents.
6. Shin J, Kepe V, Barrio JR, et al. The merits of FDDNP-PET imaging in Alzheimers disease. J Alzheimers Dis 2011;26(Suppl 3):135-45
7. Klunk WE, Wang Y, Huang G-F, et al. Uncharged thioflavin-T derivatives bind to amyloid-beta protein with high affinity and readily enter the brain. Life Sci 2001;69:1471-84
8. Mathis CA, Bacskai BJ, Kajdasz ST, et al. A lipophilic thioflavin-T derivative for positron emission tomography (PET) imaging of amyloid in brain. Bioorg Med Chem Lett 2002;12:295-8
9. Klunk WE, Engler H, Nordberg A, et al. Imaging brain amyloid in Alzheimers disease with Pittsburgh Compound-B. Ann Neurol 2004;55:306-19
10. Okamura N, Furumoto S, Harada R, et al. Novel 18F-labeled arylquinoline derivatives for noninvasive imaging of tau pathology in Alzheimer disease. J Nucl Med 2013;54:1420-7
11. Xia CF, Arteaga J,Chen G, et al. [(18)F] T807, a novel tau positron emission tomography imaging agent for Alzheimers disease. Alzheimers Dement 2013;9:666-76
12. Maruyama M, Shimada H, Suhara T, et al. Imaging of tau pathology in a tauopathy mouse model and in Alzheimer patients compared to normal controls. Neuron 2013;79:1094-108
13. Jones C, Eberhard Glaser M, Wynn D, et al. inventors. Heterocyclic compounds as imaging probes of tau pathology patent. WO090497; 2013
14. Ballatore C, Brunden KR, Piscitelli F, et al. Discovery of brain-penetrant, orally bioavailable aminothienopyridazine inhibitors of tau aggregation. J Med Chem 2010;53:3739-47. First report of brain penetrant ATPZs.
15. Ferguson GN, Valant C, Horne J, et al. 2-aminothienopyridazines as novel adenosine A1 receptor allosteric modulators and antagonists. J Med Chem 2008;51:6165-72
16. Gewald K. Heterocycles from CH-acidic nitriles. VII. 2-aminothiophene from alpha-oxo mercaptans and methyleneactive nitriles. Chem Ber 1965;98:3571-7
17. Ballatore C, Crowe A, Piscitelli F, et al. Aminothienopyridazine inhibitors of tau aggregation: Evaluation of structureactivity relationship leads to selection of candidates with desirable in vivo properties. Bioorg Med Chem 2012;20:4451-61
18. Zhang L, Villalobos A, Beck EM, et al. Design and selection parameters to accelerate the discovery of novel central nervous system positron emission tomography (PET) ligands and their application in the development of a novel phosphodiesterase 2A PET ligand. J Med Chem 2013;56:4568-79
19. Crowe A, Huang W, Ballatore C, et al. Identification of aminothienopyridazine inhibitors of tau assembly by quantitative high-throughput screening. Biochemistry 2009;48:7732-45
20. Fatouros C, Pir GJ, Biernat J, et al. Inhibition of tau aggregation in a novel Caenorhabditis elegans model of tauopathy mitigates proteotoxicity. Hum Mol Genet 2012;21:3587-603
21. Crowe A, James MJ, Lee VM, et al. Aminothienopyridazines and methylene blue affect tau fibrillization via cysteine oxidation. J Biol Chem 2013;288:11024-37
22. Chien DT, Szardenings AK, Bahri S, et al. Early clinical PET imaging results with the novel PHF-tau radioligand [F18]-T808. J Alzheimers Dis 2014;38:171-84